An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system

Moyle, Peter M.; Hartas, Jon; Henningham, Anna; Batzloff, Michael R.; Good, Michael F.; Tóth, István

doi:10.1016/j.nano.2013.01.009

Cited by 32 publications

(71 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For vaccine application, LNPs containing mRNA coding for protein antigens have been used to induce strong immune responses, such as antigen-specific antibody responses and T-cell responses in mice and rhesus macaques [ 18 , 19 ]. In addition, there is increasing evidence of the usefulness of LNPs as efficient antigen-delivery vehicles [ 20 , 21 , 22 , 23 , 24 , 25 ]. For example, by using protein antigens from dengue virus and hepatitis B virus, it has been shown that specific LNPs can enhance co-administered antigen-specific antibody responses, CD4 + T-cell responses, and CD8 + T-cell responses in mice, guinea pigs, and non-human primates without the addition of immunomodulatory adjuvant molecules [ 23 , 24 , 25 ], although the precise mechanism of adjuvanticity of specific LNPs remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Lipid Nanoparticle Acts as a Potential Adjuvant for Influenza Split Vaccine without Inducing Inflammatory Responses

et al. 2020

View full text Add to dashboard Cite

Vaccination is a critical and reliable strategy for controlling the spread of influenza viruses in populations. Conventional seasonal split vaccines (SVs) for influenza evoke weaker immune responses than other types of vaccines, such as inactivated whole-virion vaccines, although SVs are highly safe compared to other types. Here, we assessed the potential of the lipid nanoparticle (LNP) we developed as an adjuvant for conventional influenza SV as an antigen in mice. The LNP did not induce the production of cytokines such as interleukin-6 (IL-6) and IL-12 p40 by dendritic cells or the expression of co-stimulatory molecules on these cells in vitro. In contrast, an SV adjuvanted with LNP improved SV-specific IgG1 and IgG2 responses and the Th1 response compared to the SV alone in mice. In addition, SV adjuvanted with an LNP gave superior protection against the influenza virus challenge over the SV alone and was as effective as SV adjuvanted with aluminum salts in mice. The LNP did not provoke inflammatory responses such as inflammatory cytokine production and inflammatory immune cell infiltration in mice, whereas aluminum salts induced inflammatory responses. These results suggest the potential of the LNP as an adjuvant without inflammatory responses for influenza SVs. Our strategy should be useful for developing influenza vaccines with enhanced efficacy and safety.

show abstract

Section: Introductionmentioning

confidence: 99%

Lipid Nanoparticle Acts as a Potential Adjuvant for Influenza Split Vaccine without Inducing Inflammatory Responses

et al. 2020

View full text Add to dashboard Cite

show abstract

“…7,8 The concentration used in present study was similar to that previously reported for other peptide-based vaccine evaluation in vivo that utilized J14 as antigen. 21,23,40 Unlike the OVA-Q11 and (NANP) 3 -Q11 conjugates, J14-Q11 was incapable to induce visible b-sheet conformation and unable to form a dense fibrillar network as observed by CD spectroscopy (Fig. 3) and TEM (Fig.…”

Section: Discussionmentioning

confidence: 97%

Self-adjuvanting vaccine against group A streptococcus: Application of fibrillized peptide and immunostimulatory lipid as adjuvant

Azmi

Fuaad

Giddam

et al. 2014

Bioorganic & Medicinal Chemistry

Self Cite

View full text Add to dashboard Cite

Peptides are of great interest to be used as vaccine antigens due to their safety, ease of manufacturing and specificity in generating immune response. There have been massive discoveries of peptide antigens over the past decade. However, peptides alone are poorly immunogenic, which demand co-administration with strong adjuvant to enhance their immunogenicity. Recently, fibril-forming peptides such as Q11 and lipoamino acid-based carrier have been identified to induce substantial immune responses when covalently linked to peptide epitope. In this study, we have incorporated either Q11 or lipoamino acids to a peptide epitope (J14) derived from M protein of group A streptococcus to develop self-adjuvanting vaccines. J14, Q11 and lipoamino acids were also conjugated together in a single vaccine construct in an attempt to evaluate the synergy effect of combining multiple adjuvants. Physicochemical characterization demonstrated that the vaccine constructs folded differently and self-assembled into nanoparticles. Significantly, only vaccine constructs containing double copies of lipoamino acids (regardless in conjugation with Q11 or not) were capable to induce significant dendritic cells uptake and subsequent J14-specific antibody responses in non-sizes dependent manners. Q11 had minimal impact in enhancing the immunogenicity of J14 even when it was used in combination with lipoamino acids. These findings highlight the impact of lipoamino acids moiety as a promising immunostimulant carrier and its number of attachment to peptide epitope was found to have a profound effect on the vaccine immunogenicity.

show abstract

“…The LCP system has also been applied to the delivery of multiepitope-based polypeptides [102]. A semisynthetic vaccine against G AS was produced by maleimide conjugation of LCP lipidic moiety 5 (see Fig.…”

Section: Lipid-based Self-assembled Nanostructurementioning

confidence: 99%

The application of self-assembled nanostructures in peptide-based subunit vaccine development

Zhao

Chandrudu

Skwarczynski

et al. 2017

European Polymer Journal

Self Cite

View full text Add to dashboard Cite

Please cite this article as: Zhao, G., Chandrudu, S., Skwarczynski, M., Toth, I., The application of self-assembled nanostructures in peptide-based subunit vaccine development, European Polymer Journal (2017), doi: http:// dx.doi.org/10. 1016/j.eurpolymj.2017.02.014 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 1The application of self-assembled nanostructures in

show abstract

An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system

Cited by 32 publications

References 46 publications

Lipid Nanoparticle Acts as a Potential Adjuvant for Influenza Split Vaccine without Inducing Inflammatory Responses

Lipid Nanoparticle Acts as a Potential Adjuvant for Influenza Split Vaccine without Inducing Inflammatory Responses

Self-adjuvanting vaccine against group A streptococcus: Application of fibrillized peptide and immunostimulatory lipid as adjuvant

The application of self-assembled nanostructures in peptide-based subunit vaccine development

Contact Info

Product

Resources

About